Office of Translational Sciences
E392787
The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Office of Translational Sciences canonical | 2 |
| https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-translational-sciences | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T3849413 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Office of Translational Sciences Context triple: [Center for Drug Evaluation and Research, oversees, Office of Translational Sciences]
-
A.
National Center for Advancing Translational Sciences
The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
-
B.
Division of Extramural Research
The Division of Extramural Research is a branch of the National Human Genome Research Institute that oversees and funds genome-related research conducted outside the institute.
-
C.
Center for Scientific Review
The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
-
D.
Center for Health and Biosciences
The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
-
E.
Division of Intramural Research
The Division of Intramural Research is the National Heart, Lung, and Blood Institute’s in-house research arm that conducts basic, translational, and clinical studies on cardiovascular, pulmonary, and blood-related diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Office of Translational Sciences Target entity description: The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
-
A.
National Center for Advancing Translational Sciences
The National Center for Advancing Translational Sciences is a U.S. biomedical research center focused on accelerating the development and delivery of new diagnostics, treatments, and cures by improving the translational science process.
-
B.
Division of Extramural Research
The Division of Extramural Research is a branch of the National Human Genome Research Institute that oversees and funds genome-related research conducted outside the institute.
-
C.
Center for Scientific Review
The Center for Scientific Review is the National Institutes of Health component responsible for overseeing the peer review of most grant applications to ensure scientific merit and integrity in funding decisions.
-
D.
Center for Health and Biosciences
The Center for Health and Biosciences is a research and policy institute focused on health care, biomedical innovation, and related public policy issues.
-
E.
Division of Intramural Research
The Division of Intramural Research is the National Heart, Lung, and Blood Institute’s in-house research arm that conducts basic, translational, and clinical studies on cardiovascular, pulmonary, and blood-related diseases.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
FDA office
ⓘ
scientific office ⓘ |
| activity |
collaborate with external scientific and academic partners
ⓘ
conduct regulatory science research ⓘ develop and apply modeling and simulation in drug development ⓘ develop scientific policies and guidance ⓘ evaluate clinical pharmacology aspects of drug applications ⓘ provide quantitative and statistical support for drug review ⓘ provide scientific training and education in regulatory science ⓘ support biomarker development and qualification ⓘ support clinical trial design and analysis ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| field |
biomedical research
ⓘ
biostatistics ⓘ clinical pharmacology ⓘ drug development ⓘ pharmacometrics ⓘ regulatory science ⓘ translational medicine ⓘ |
| focus |
benefit–risk assessment
ⓘ
biomarkers and surrogate endpoints ⓘ dose optimization ⓘ effectiveness of human drugs ⓘ exposure–response relationships ⓘ innovative clinical trial methodologies ⓘ patient-focused drug development ⓘ quantitative methods in drug development ⓘ safety of human drugs ⓘ |
| locatedIn |
Maryland
ⓘ
Silver Spring, Maryland ⓘ United States of America ⓘ
surface form:
United States
|
| mission |
advance translation of biomedical research into safe and effective drug therapies
ⓘ
develop and apply regulatory science tools and methods ⓘ improve efficiency and success of drug development ⓘ support regulatory decision-making for human drugs ⓘ |
| parentOrganization |
Center for Drug Evaluation and Research
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| partOf |
Center for Drug Evaluation and Research
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulates |
aspects of human nonprescription drugs
ⓘ
aspects of human prescription drugs ⓘ |
| usesMethod |
advanced biostatistical methods
ⓘ
clinical trial simulation ⓘ model-informed drug development ⓘ pharmacokinetic and pharmacodynamic analysis ⓘ |
| website |
Office of Translational Sciences
self-linksurface differs
ⓘ
surface form:
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-translational-sciences
|
| worksOn |
biologics license applications
ⓘ
investigational new drug applications ⓘ new drug applications ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Office of Translational Sciences Description of subject: The Office of Translational Sciences is a scientific office within the U.S. Food and Drug Administration that advances the translation of biomedical research into safe and effective drug therapies through regulatory science, research, and policy development.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
Office of Translational Sciences
→
website
→
Office of Translational Sciences
self-linksurface differs
ⓘ
this entity surface form:
https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-translational-sciences